Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 55 of 159 for:    colon cancer AND Capecitabine AND Fluorouracil

Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients (CAPTEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02414009
Recruitment Status : Unknown
Verified March 2016 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Recruitment status was:  Recruiting
First Posted : April 10, 2015
Last Update Posted : March 16, 2017
Sponsor:
Information provided by (Responsible Party):
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:

Open-label, randomized, multicenter, Phase II trial designed to estimate the efficacy of CAPTEM versus FOLFIRI as second line treatment in MGMT methylated, RAS mutated advanced CRC patients who have progressed on or after first-line oxaliplatin containing chemotherapy for metastatic disease. MGMT will be assessed centrally at Pathology Department of Fondazione IRCCS Istituto Nazionale dei Tumori prior to enrollment. A minimum of ten 3-micron unstained sections on charged slides of tumor will be required and methylation status will be provided within a maximum of seven days to the Study Centers. Presence of RAS mutation will be assessed at each local participating center. Eligible patients will be randomized in a 1:1 ratio to one of two treatment arms:

  • Arm A (experimental arm): CAPTEM
  • Arm B (control arm): FOLFIRI Study treatment will be given in cycles repeated every 28 days for Arm A and every 14 days for Arm B. Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 9 to 14 every 28 days. Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 6 cycles in Arm A and up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal. Randomization will be stratified across the treatment arms by the following predefined stratification variables: disease progression within 9 months from the start of first-line oxaliplatin-containing chemotherapy (< vs. ≥9 months); prior bevacizumab in combination with oxaliplatin-based chemotherapy (yes vs. no). Efficacy assessments will be performed every 2 cycles in Arm A and every 4 cycles in Arm B until progression. The study is expected to enrol approximately 82 patients who meet the eligibility criteria.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Capecitabine Drug: Temozolomide Drug: Irinotecan Drug: Fluorouracil Drug: Leucovorin Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Randomized, Multicenter, Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced, MGMT Methylated, RAS Mutated Colorectal Cancer
Study Start Date : September 2014
Estimated Primary Completion Date : September 2017
Estimated Study Completion Date : September 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CAPTEM
Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
Drug: Capecitabine
Drug: Temozolomide
Active Comparator: FOLFIRI

Patients in Arm B will receive FOLFIRI chemotherapy starting Day

1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal.

Drug: Irinotecan
Drug: Fluorouracil
Drug: Leucovorin



Primary Outcome Measures :
  1. Progression-free survival of FOLFIRI versus CAPTEM [ Time Frame: 30 months ]

Secondary Outcome Measures :
  1. Response rate [ Time Frame: 30 months ]
    Evaluation of activity of the two regimens, as measured by response rate.

  2. Overall survival of FOLFIRI versus CAPTEM [ Time Frame: 30 months ]
  3. Number of Adverse events by CTCAE version 4.0 [ Time Frame: 30 months ]
  4. Quality of life as measured by EORTC QLQ - CR29 QLQ-C30 [ Time Frame: 30 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Informed Consent Form
  • Histologically or cytologically confirmed adenocarcinoma of the colon and/or rectum, with MGMT promoter methylation and RAS mutation.
  • Progressive disease on or after a first-line oxaliplatin containing chemotherapy regimen for mCRC with or without bevacizumab or other anti-angiogenic drugs. Patients must have received oxaliplatin-containing chemotherapy for ≥ 3 months. No more than one prior chemotherapy regimen for metastatic disease is allowed. 8
  • Disease measurableRECIST v1.1
  • Age ≥ 18 years and ≤ 75 years
  • Life expectancy ≥ 12 weeks
  • ECOG Performance Status of 0 1
  • Adequate hematologic and end-organ function, defined by laboratory results obtained within 14 days prior to first administration: ANC ≥ 1500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9.0 g/dL Albumin ≥ 2.5 g/dL
  • Total bilirubin ≤ 1.5 × the upper limit of normal (ULN)
  • AST, ALT, and/or alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions: Patients with documented hepatic metastases are eligible with AST, ALT, and/or alkaline phosphatase ≤ 5 × ULN. Patients with documented bone metastases are eligible with alkaline phosphatase ≤ 5 × ULN.
  • Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation: (140 − age) × (weight in kg) × (0.85 if female) 72 × (serum creatinine in mg/dL)
  • INR and aPTT ≤ 1.5 × ULN
  • documented agreement (by patient and/or partner) to use an effective means of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study and for 60 days for female patients or 150 days for male patients with partners of childbearing potential after the last infusion of study treatment.
  • Consent to provide mandatory archival tumor tissue for biomarker testing

Exclusion Criteria:

  • Prior treatment with irinotecan and temozolomide
  • Major surgical procedure within 4 weeks and radiotherapy within 2 weeks prior to Day 1 Cycle 1
  • Symptomatic hypercalcemia requiring continued use of bisphosphonate.
  • Known clinically significant dihydropyrimidine 9 dehydrogenase deficiency
  • Current severe, uncontrolled systemic disease Active infection requiring IV antibiotics
  • History of heart failure of any New York Heart Association criteria or serious cardiac arrhythmia requiring treatment (except for atrial fibrillation and paroxysmal supraventricular tachycardia)
  • History of myocardial infarction within 6 months prior to Cycle 1, Day 1, or history of unstable angina
  • Known clinically significant liver disease,or current alcohol abuse
  • History of bleeding diathesis or coagulopathy other than that due to anticoagulation therapy
  • Patients receiving oral coumarin-derived anticoagulants
  • Active haemoptysis within 30 days prior to Cycle 1, Day 1
  • HIV infection
  • Untreated/active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible provided they meet all of the following criteria: Measurable disease outside the CNS as defined by RECIST v1.1.Radiotherapy completed ≥ 4 weeks prior to Cycle, 1 Day
  • Pregnancy or lactation. Women of childbearing potential (including those who have had a tubal ligation) must have a documented negative serum pregnancy test within 14 days prior to Cycle 1, Day 1.
  • Inability to take oral medications.
  • Malignancies other than CRC within 3 years prior to randomization, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02414009


Contacts
Layout table for location contacts
Contact: Filippo de Braud, MD 02-2390 ext 3066 filippo.debraud@istitutotumori.mi.it
Contact: Filippo Pietrantonio, MD 02-2390 ext 3807 filippo.pietrantonio@istitutotumori.mi.it

Locations
Layout table for location information
Italy
Fondazione IRCCS Istituto Nazionale Tumori Recruiting
Milan, Mi, Italy, 20133
Contact: Filippo Pietrantonio, MD    00390223903807    filippo.pietrantonio@istitutotumori.mi.it   
Contact       trialcenter@istitutotumori.mi.it   
Principal Investigator: Filippo de Braud, MD         
Sub-Investigator: Filippo Pietrantonio, MD         
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Layout table for additonal information
Responsible Party: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier: NCT02414009     History of Changes
Other Study ID Numbers: CAPTEM
First Posted: April 10, 2015    Key Record Dates
Last Update Posted: March 16, 2017
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Capecitabine
Fluorouracil
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Irinotecan
Temozolomide
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents